AB0246 PREDICTORS OF FATIGUE IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVE BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Abstract

Background Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. Despite being a very disabling symptom, the variables that predict it are still unknown. Objectives To identify potential factors associated with fatigue. Methods Cross-sectional study. 60 patients were included, patients were being followed up in the rheumatology outpatient clinic of Hospital Clinico San Carlos, Madrid, Spain. Data were collected between July 2018 and January 2019. All patients met the ACR/EULAR 2010 criteria and they were in treatment with Biological agents or Targeted Synthetic DMARDs. Main variable: Fatigue was assessed by the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) and the Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scale (BRAF-NRS). Covariables: Sociodemographic, clinical, Disease-related variables and treatment. Statistical analysis. A descriptive analysis was carried out for the different variables. To identify factors independently associated to BRAF-MDQ a multivariable linear regression was applied. Results were expressed as β with their corresponding 95% CI. A value of p Results A total of 60 patients, comprising of 53 females (88%) and 7 males (12%) with a mean age of 56.45±11.89 years and mean disease duration of 14.11±7.79 years were evaluated. RF was positive in 60% of patients. 65% of the patients were in active on work and 23% were retired. Regarding comorbidities, 43% had dyslipidemia, 42% hypertension, 17% hypothyroidism and 15% depression. The DAS28-ESR and SDAI scores of the patients were 2.68 ± 0.86, 8.56 ± 5.96 respectively. The rest of the clinical, treatment characteristics, and the scores of the fatigue instruments used in the study are shown in Table 1. Physical dimension was the most affected according to patients, who perceive an average severity and affectation, and insufficient coping. The factors affecting the total BRAF-MDQ was evaluated in multivariate analyze Table 2. We found that patients with Disability (p Conclusion Fatigue is a substantial symptom in RA patients and should be evaluated on the daily clinical practice. The results of our study indicated that disability and type of treatment were the dominant factors in the experience and degree of fatigue. Disease activity (DAS28 and SDAI) was not associated to fatigue. The evaluation and management of fatigue should be one of the objectives in the treatment of patients with RA Disclosure of Interests None declared